These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 35680599

  • 1. [Influence of the number of high-risk cytogenetic abnormalities on the clinical characteristics and prognosis in 360 patients with newly diagnosed multiple myeloma].
    Chen Z, Xia Y, Guo R, Zhang R, Qiu HR, Jin YY, Li JY, Chen LJ.
    Zhonghua Xue Ye Xue Za Zhi; 2022 May 14; 43(5):408-413. PubMed ID: 35680599
    [Abstract] [Full Text] [Related]

  • 2. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
    Mina R, Musto P, Rota-Scalabrini D, Paris L, Gamberi B, Palmas A, Aquino S, de Fabritiis P, Giuliani N, De Rosa L, Gozzetti A, Cellini C, Bertamini L, Capra A, Oddolo D, Vincelli ID, Ronconi S, Pavone V, Pescosta N, Cea M, Fioritoni F, Ballanti S, Grasso M, Zamagni E, Belotti A, Boccadoro M, Gay F.
    Lancet Oncol; 2023 Jan 14; 24(1):64-76. PubMed ID: 36528035
    [Abstract] [Full Text] [Related]

  • 3. Impact of autologous stem cell transplantation (ASCT) on progression free survival (PFS) in newly diagnosed multiple myeloma patients (NDMM) with high risk cytogenetic abnormalities.
    Guman T, Sykora J.
    Bratisl Lek Listy; 2024 Jan 14; 125(1):9-11. PubMed ID: 38041839
    [Abstract] [Full Text] [Related]

  • 4. [Prognostic analysis of 182 newly diagnosed multiple myeloma patients with high risk cytogenetic abnormalities].
    Liu XL, Bai J, Fan HQ, Yang YP, Yue TT, Zhang Y, Yang PY, Gao SJ, Li W, Jin FY.
    Zhonghua Xue Ye Xue Za Zhi; 2019 Aug 14; 40(8):644-649. PubMed ID: 31495130
    [Abstract] [Full Text] [Related]

  • 5. Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice.
    Mizuguchi M, Okamoto Y, Yagi H, Kagawa K, Sekimoto E, Shibata H, Shigekiyo T, Ozaki S.
    Int J Hematol; 2023 May 14; 117(5):718-728. PubMed ID: 36692689
    [Abstract] [Full Text] [Related]

  • 6. Complex karyotype determined using conventional cytogenetic analysis is a poor prognostic factor in patients with multiple myeloma.
    Uryu H, Mishima Y, Ishihara Y, Shirouchi Y, Yamauchi N, Hirano M, Hirano K, Teramoto Y, Yoshida K, Maruyama D.
    J Clin Exp Hematop; 2024 May 14; 64(1):10-20. PubMed ID: 38538316
    [Abstract] [Full Text] [Related]

  • 7. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.
    Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, Silbermann R, Dhakal B, Bal S, Giri S, D'Souza A, Hall AC, Hardwick P, Omel J, Cornell RF, Hari P, Callander NS.
    Lancet Haematol; 2023 Nov 14; 10(11):e890-e901. PubMed ID: 37776872
    [Abstract] [Full Text] [Related]

  • 8. Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma.
    Tao Y, Jin S, Yang D, Pan M, Ouyang W, Liu Y, Wang Y, Zhang W, Mi J.
    BMC Cancer; 2024 Apr 02; 24(1):406. PubMed ID: 38565996
    [Abstract] [Full Text] [Related]

  • 9. At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China.
    Shen M, Yang G, Li X, Geng C, Huang Z, Chen W.
    Leuk Lymphoma; 2021 Dec 02; 62(12):2992-3001. PubMed ID: 34219587
    [Abstract] [Full Text] [Related]

  • 10. [Effects of extramedullary disease on patients with newly diagnosed multiple myeloma].
    Tao Y, Jin SW, Wang Y, Tang SJ, Liu YF, Xu J, Pan MM, Zhang WP, Mi JQ.
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jan 14; 44(1):48-54. PubMed ID: 36987723
    [Abstract] [Full Text] [Related]

  • 11. Chromosome 1q21 Aberrations Are Poor Prognostic Factors for Newly Diagnosed Multiple Myeloma Patients.
    Wang T, Geng C, Yang G, Zhou H, Zhang Z, Jian Y, Chen W.
    J Clin Lab Anal; 2024 Sep 14; 38(17-18):e25072. PubMed ID: 39263925
    [Abstract] [Full Text] [Related]

  • 12. Myc rearrangement redefines the stratification of high-risk multiple myeloma.
    Jin X, Li H, Zhang D, Liu S, Song Y, Zhang F, Li Z, Zhuang J.
    Cancer Med; 2024 Jun 14; 13(11):e7194. PubMed ID: 38845529
    [Abstract] [Full Text] [Related]

  • 13. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
    Huang WY, Zou DH, Liu W, An G, Xu Y, Sui WW, Deng SH, Li CW, Liu H, Li J, Qiu LG.
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jun 14; 39(6):496-500. PubMed ID: 30032568
    [Abstract] [Full Text] [Related]

  • 14. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma.
    Pasvolsky O, Ghanem S, Milton DR, Masood A, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH.
    Transplant Cell Ther; 2023 Dec 14; 29(12):757-762. PubMed ID: 37673125
    [Abstract] [Full Text] [Related]

  • 15. [Clinical characteristics and prognosis of patients with newly-diagnosed multiple myeloma with t(11;14)].
    Wang Y, Liu YF, Tao Y, Jin SW, Mi JQ.
    Zhonghua Yi Xue Za Zhi; 2022 Sep 27; 102(36):2868-2873. PubMed ID: 36153872
    [Abstract] [Full Text] [Related]

  • 16. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
    Li X, Chen W, Wu Y, Li J, Chen L, Fang B, Feng Y, Liu J, Chen M, Gu J, Huang B, Li J.
    Oncologist; 2019 Nov 27; 24(11):e1132-e1140. PubMed ID: 31455749
    [Abstract] [Full Text] [Related]

  • 17. [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma].
    Liu XL, Yang YP, Bai J, Yue TT, Yang PY, Zhang Y, Fan HQ, Li W, Jin FY.
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov 14; 40(11):912-917. PubMed ID: 31856439
    [Abstract] [Full Text] [Related]

  • 18. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
    Shin HJ, Kim K, Lee JJ, Song MK, Lee EY, Park SH, Kim SH, Jang MA, Kim SJ, Chung JS.
    Clin Lymphoma Myeloma Leuk; 2015 Apr 14; 15(4):227-35. PubMed ID: 25812994
    [Abstract] [Full Text] [Related]

  • 19. [The therapeutic effect and prognostic value of oligoclonal bands after autologous stem cell transplant in patients with multiple myeloma].
    Shi QL, Xu Y, Wang J, Jin YY, Zhang R, Li JY, Chen LJ.
    Zhonghua Yi Xue Za Zhi; 2024 Feb 20; 104(7):514-520. PubMed ID: 38317363
    [Abstract] [Full Text] [Related]

  • 20. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience.
    Pasvolsky O, Gaballa MR, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Tang G, Lin P, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH.
    Transplant Cell Ther; 2023 Apr 20; 29(4):260.e1-260.e6. PubMed ID: 36646323
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.